DiaMedica Therapeutics (DMAC) announced the appointment of Julie Krop as chief medical officer, effective immediately. Krop will succeed Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. She joins DiaMedica from PureTech Health (PRTC), where she was CMO and Head of Development.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Appoints New Chief Medical Officer
- DiaMedica Therapeutics files to sell 8.61M common shares for holders
- ReMEDy2 Trial: A New Hope for Acute Ischemic Stroke Treatment?
- DiaMedica Therapeutics Secures $30.1 Million in Private Placement
- DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement